title BeiGene Reveals Promising Results of Combination Therapy for High-risk CLL/SLL at EHA2024 Congress

Published / Modified Jun 16 2024
CSIMarket Team / CSIMarket.com

BeiGene Presents Promising Data from SEQUOIA Study at EHA2024 for First-line Treatment of High-risk CLL/SLL

BeiGene, a global oncology company, recently announced the presentation of new data from the SEQUOIA study at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain. The data highlights the combination of BRUKINSA (Zanubrutinib) with Venetoclax for the first-line treatment of high-risk CLL/SLL.

The SEQUOIA study focuses on Arm D, where BRUKINSA is used in conjunction with Venetoclax. This combination therapy shows promising results for patients with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The oral presentation, known as Abstract S160, will provide detailed insights into the efficacy and safety of this treatment approach.

BRUKINSA, a potent and selective Bruton?s tyrosine kinase (BTK) inhibitor, has already demonstrated its effectiveness as a standalone treatment for CLL/SLL. The addition of Venetoclax, a BCL-2 inhibitor, further enhances the potential benefits of this therapy. The data from Arm D of the SEQUOIA study will shed light on the synergistic effects of combining these two targeted therapies.

In another news, BeiGene has decided to conclude its partnership with NewBridge Pharmaceuticals FZ LLC in the Middle East and Africa (MENA) region. This strategic decision aligns with BeiGene's goal to expand its presence and directly manage operations in this region. The collaboration between the two companies, which began in 2020, focused on sales, distribution, and commercialization activities for BRUKINSA.

At EHA2024, BeiGene will also present new data from its hematology portfolio and pipeline. With 28 abstracts accepted at the congress, four of them will be orally presented. This highlights BeiGene's dedication to bringing high-quality therapies to patients worldwide.

The presentation of data from the SEQUOIA study at EHA2024 indicates the potential of BRUKINSA in combination with Venetoclax for the first-line treatment of high-risk CLL/SLL. This combination therapy may offer new hope for patients, and further research will continue to explore its efficacy and safety.

Sources for this article: Beigene Ltd Press release, News Wire, Globe Newswire, Business wire, Pr newswire.... and CSIMarket.com Customer Analytics Research for Beigene Ltd


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com